Inge Thulin - Merck Independent Director
| MRK Stock | EUR 140.90 0.95 0.67% |
Director
Mr. Inge G. Thulin is Independent Director of the Company. He is chairman of the board, president and chief executive officer of 3M, a company that applies science in collaborative ways to improve lives and create solutions to global problems. 3M has also been widely recognized for its commitment to sustainability and diversity. Mr. Thulin began his career with 3M in Europe in 1979 and since then has assumed several key roles of increasing responsibility, most recently serving as chief operating officer prior to his current role. Mr. Thulin earned degrees in economics and marketing from the University of Gothenburg in Sweden. He is a National Committee on U.S.China Relations Honoree, has received the Peter G. Peterson Business Statesmanship Award from the Committee for Economic Development, the Lucia Trade Award from the SwedishAmerican Chamber of Commerce and the Hendrickson Medal for Ethical Leadership. Most recently, Mr. Thulin was honored by Junior Achievement of The Upper Midwest, Inc. as a 2016 Business Hall of Fame Laureate. since 2018.
| Age | 65 |
| Tenure | 6 years |
Merck Company Leadership Team
Elected by the shareholders, the Merck's board of directors comprises two types of representatives: Merck inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Merck. The board's role is to monitor Merck's management team and ensure that shareholders' interests are well served. Merck's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Merck's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Thomas Glocer, Independent Director | ||
| Pamela Craig, Independent Director | ||
| Jennifer Zachary, Executive Vice President, General Counsel, Corporate Secretary | ||
| Patricia Russo, Independent Director | ||
| Franklin Clyburn, Executive Vice President Chief Commercial Officer | ||
| Rita Karachun, Senior Vice President - Finance, Global Controller | ||
| Christine Seidman, Independent Director | ||
| Dean Li, Executive Vice President and Presidentident, Merck Research Laboratories | ||
| Robert Davis, Executive Vice President, Global Services, Chief Financial Officer | ||
| Kathy Warden, Independent Director | ||
| Thomas Cech, Independent Director | ||
| Michael Nally, Executive Vice President, Chief Marketing Officer | ||
| Paul Rothman, Independent Director | ||
| Mary Coe, Independent Director | ||
| Michael Fleming, Senior Vice President Chief Ethics and Compliance Officer | ||
| Roger Perlmutter, Executive Vice President and Presidentident - Merck Research Laboratories | ||
| Steven Mizell, Executive Vice President, Chief Human Resources Officer, Human Resources | ||
| Sanat Chattopadhyay, Executive Vice President and President - Merck Manufacturing Division | ||
| Richard DeLuca, Executive Vice President and Presidentident - Merck Animal Health | ||
| Kenneth Frazier, Chairman of the Board, President, Chief Executive Officer | ||
| Peter Wendell, Independent Director | ||
| Leslie Brun, Lead Independent Director | ||
| Julie Gerberding, Executive Vice President and Chief Patient Officer, Strategic Communications, Global Public Policy and Population Health | ||
| Inge Thulin, Independent Director |
Merck Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Merck a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Current Valuation | 87.36 B | |||
| Price To Book | 2.69 X | |||
| Price To Sales | 3.49 X | |||
| Revenue | 19.69 B | |||
| EBITDA | 5.96 B | |||
| Net Income | 3.06 B | |||
| Total Debt | 7.93 B | |||
| Cash Flow From Operations | 4.62 B | |||
| Price To Earnings To Growth | 3.00 X | |||
| Number Of Employees | 42 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Information and Resources on Investing in Merck Stock
When determining whether Merck Company is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Merck Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Merck Company Stock. Highlighted below are key reports to facilitate an investment decision about Merck Company Stock:Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Merck Company. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.